Haskett R F
Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(2-3):129-35. doi: 10.1016/0278-5846(87)90050-9.
A small percentage of women describe a prominent dysphoric disturbance that is present during the premenstrual week, remits soon after the onset of menses and produces significant impairment in domestic, social or occupational functioning. Premenstrual dysphoric disorder must be distinguished from minor premenstrual emotional changes, from dysmenorrhea and from premenstrual exacerbations of psychiatric illness. Diagnostic evaluation should include the prospective assessment of symptoms over at least two complete menstrual cycles. Although the pathophysiology of premenstrual dysphoric disorder is linked to cycling of the intact hypothalamo-pituitary-gonadal axis, many studies have contained serious methodological weaknesses and no single etiological theory has received widespread support. No single pharmacological treatment has been shown to be clearly more effective than placebo in controlled studies and premenstrual dysphoric disorder appears to respond favorably to most interventions in uncontrolled studies. Interruption of pituitary-ovarian cycling will alleviate premenstrual symptoms, but treatments of this type cannot be recommended for general use until potential hazards are clarified.
一小部分女性描述在经前一周会出现明显的烦躁不安,月经开始后不久症状就会缓解,且在家庭、社交或职业功能方面产生显著损害。经前烦躁障碍必须与轻微的经前情绪变化、痛经以及精神疾病的经前加重相区分。诊断评估应包括对至少两个完整月经周期症状的前瞻性评估。尽管经前烦躁障碍的病理生理学与完整的下丘脑 - 垂体 - 性腺轴的周期性变化有关,但许多研究存在严重的方法学缺陷,且没有单一的病因理论得到广泛支持。在对照研究中,没有一种单一的药物治疗被证明比安慰剂明显更有效,而在非对照研究中,经前烦躁障碍似乎对大多数干预措施反应良好。中断垂体 - 卵巢周期会缓解经前症状,但在潜在危害明确之前,不建议普遍使用这类治疗方法。